Biolex gives Unithink e-PRO a trial role

An electronic patient-reported outcome system has played a key role in a Phase II trial. The trial yielded positive results for a hepatitis C treatment from Biolex Therapeutics.

During the trial, subjects reported flu-like adverse events on a daily basis through the ePRO system. In addition to the ePRO data, researchers recorded adverse events using traditional weekly assessments at the trial sites. A comparison of the data from both reporting methods confirmed the ePRO results, the company says. 

Biolex worked with solutions provider Unithink to develop the system, according to a company spokesman in an email. The Biolex clinical team worked internally to customize the ePRO infrastructure to the data collection and analysis needs. It was a "fairly straightforward implementation," the spokesman says. And the reporting method yielded insight to subjects' experiences with the side effects and the impact on their daily activities. 

The drug being tested, a 480-microgram dose of Locteron, yielded a statistically significant reduction in the frequency and severity of the flu-like adverse events among subjects compared with the PEG-Intron control treatment. The trial demonstrated strong anti-viral response of the experimental treatment, according to Biolex.

- see the Biolex release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.